Fundamentals of Pharmacokinetics to Assess the Correlation Between Plasma Drug Concentrations and Different Blood Sampling Methods

2019 ◽  
Vol 36 (2) ◽  
Author(s):  
Wei-Ching Chen ◽  
Pei-Wei Huang ◽  
Wan-Ling Yang ◽  
Yen-Lun Chen ◽  
Ying-Ning Shih ◽  
...  
Keyword(s):  
Sampling Methods ◽  
Blood Sampling ◽  
Plasma Drug ◽  
Drug Concentrations ◽  
Plasma Drug Concentrations

scholarly journals Impact of hepatitis C and liver fibrosis on antiretroviral plasma drug concentrations in HIV-HCV co-infected patients: the HEPADOSE study

2010 ◽  
Vol 65 (11) ◽  
pp. 2445-2449 ◽  
Author(s):  
S. Dominguez ◽  
J. Ghosn ◽  
G. Peytavin ◽  
M. Guiguet ◽  
R. Tubiana ◽  
...  
Keyword(s):  
Hepatitis C ◽  
Liver Fibrosis ◽  
Plasma Drug ◽  
Drug Concentrations ◽  
Plasma Drug Concentrations

Clinical responses and plasma drug concentrations associated with different infusions of xylazine and ketamine in horses

2000 ◽  
Vol 27 (1) ◽  
pp. 58-59
Author(s):  
KR Mama ◽  
AE Wagner ◽  
EP Steffey ◽  
C Kollias-Baker ◽  
PW Hellyer ◽  
...  
Keyword(s):  
Plasma Drug ◽  
Drug Concentrations ◽  
Clinical Responses ◽  
Plasma Drug Concentrations

scholarly journals Drug plasma trough concentrations during treatment with daclatasvir and sofosbuvir are associated respectively with liver impairment and with renal dysfunction in HIV/HCV co-infected patients

2019 ◽  
Author(s):  
Ilaria Mastrorosa ◽  
Massimo Tempestilli ◽  
Stefania Notari ◽  
Patrizia Lorenzini ◽  
Gabriele Fabbri ◽  
...  
Keyword(s):  
Renal Dysfunction ◽  
Virologic Response ◽  
Patient Treatment ◽  
Limited Information ◽  
Plasma Drug ◽  
Related Factors ◽  
Immunological Parameters ◽  
Liver Impairment ◽  
Drug Concentrations ◽  
Plasma Drug Concentrations

Abstract Background Sofosbuvir (SOF) plus daclatasvir (DCV) achieved high rates of sustained virologic response (SVR) with no difference according to HIV serostatus. Only limited information is available on the pharmacokinetics variability of SOF and DCV in HIV/HCV co-infected patients. Aim was to evaluate the association of plasma drug concentrations (Ctrough) of SOF and of DCV with patient-, treatment-, and disease-related factors in the real-world setting of HIV/HCV co-infected persons. Methods HIV/HCV co-infected patients, undergoing SOF plus DCV treatment, were prospectively enrolled. At baseline, week4 (W4), end of treatment (EOT), and after-EOT, biochemical and viro-immunological parameters were assessed. FIB-4 score and CKD-EPI equation were used for estimation of liver disease and glomerular filtration rate (eGFR), respectively. SOF, SOF metabolite (GS-331007), and DCV Ctrough were measured at W4 and week8 (W8), and the mean value (mean-Ctrough) was calculated Results Thirty-five patients were included (SVR 94%). Increasing GS-331007 mean-Ctrough significantly correlated with decreasing eGFR at W4 (rho=-0.36; p=0.037) and EOT (rho=-0.34; p=0.048). Between DCV mean-Ctrough and FIB-4, a significant correlation was observed at all time-points: baseline (rho=-0.35; p=0.037), W4 (rho=-0.44; p=0.008), EOT (rho=-0.40; p=0.023), after-EOT (rho=-0.39; p=0.028). Conclusion In HIV/HCV co-infected patients receiving SOF plus DCV, plasma drug concentrations are associated with renal dysfunction for GS-331007 and with liver impairment for DCV. Though clinical and therapeutically relevance of these findings may apparently be limited, growth of clinicians’ knowledge on DAA exposure in difficult-to-treat patients, as cirrhotic and renal impaired subjects, can be relevant in single cases.

Plasma drug concentrations and clinical effects of a peripheral alpha-2-adrenoceptor antagonist, MK-467, in horses sedated with detomidine

2013 ◽  
Vol 40 (3) ◽  
pp. 257-264 ◽  
Author(s):  
Mari H Vainionpää ◽  
Marja R Raekallio ◽  
Soile AE Pakkanen ◽  
Ville Ranta-Panula ◽  
Valtteri M Rinne ◽  
...  
Keyword(s):  
Clinical Effects ◽  
Plasma Drug ◽  
Adrenoceptor Antagonist ◽  
Drug Concentrations ◽  
Plasma Drug Concentrations

Opiate-induced Rhabdomyolysis

1985 ◽  
Vol 4 (1) ◽  
pp. 71-74 ◽  
Author(s):  
P.G. Blain ◽  
R.J.M. Lane ◽  
D.N. Bateman ◽  
M.D. Rawlins
Keyword(s):  
Renal Failure ◽  
Creatine Kinase ◽  
Acute Renal Failure ◽  
Clinical Evidence ◽  
Elevated Serum ◽  
Plasma Drug ◽  
Drug Concentrations ◽  
Serum Aspartate Aminotransferase ◽  
Plasma Drug Concentrations ◽  
Serum Myoglobin

Three patients with opiate self-poisoning developed acute muscle damage with elevated serum aspartate aminotransferase and creatine kinase activities, increased serum myoglobin concentrations, raised plasma creatinine concentrations, hypocalcaemia and hyperphosphataemia. These abnormalities gradually resolved over 7-10 days, but recovery was complicated due to the development of acute renal failure (requiring haemodialysis) in one patient. Plasma drug concentrations, shortly after admission, in the patients taking dihydrocodeine and morphine were grossly elevated (184 and 60 μg/l respectively). Clinical evidence of myopathy was minimal in all three patients and muscle biopsy of one patient was normal at 7 days.

scholarly journals ABC of monitoring drug therapy. Measuring plasma drug concentrations.

BMJ ◽  
1992 ◽  
Vol 305 (6861) ◽  
pp. 1078-1080 ◽  
Author(s):  
J. K. Aronson ◽  
M. Hardman
Keyword(s):  
Drug Therapy ◽  
Plasma Drug ◽  
Monitoring Drug ◽  
Drug Concentrations ◽  
Plasma Drug Concentrations
Sign in / Sign up

Export Citation Format

Share Document